Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

M. Margerges



Author of

  • +

    P1.10 - Poster Session 1 - Chemotherapy (ID 204)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.10-049 - Efficacy of bevacizumab combined with paclitaxel and carboplatin: A second line treatment of elderly patients with advanced non-small cell carcinoma (NSCLC) (ID 2938)

      09:30 - 09:30  |  Author(s): M. Margerges

      • Abstract

      Background
      The aim of this phase II study was to assess the efficacy and safety of paclitaxel combined with carboplatin plus bevacizumab as a second line treatment of elderly patients with advanced NSCLC.

      Methods
      Twenty one elderly patients with NSCLC who previously received only one line of chemotherapy were enrolled into this study between March 2009 and March 2013. All patients received paclitaxel 175 mg/m[2] followed by carboplatin AUC of 5, and followed by bevacizumab 15mg/kg, all agents were given via I.V infusion on day 1 and the cycle was repeated every 21 days for maximum 6-8 cycles. Patients who attained at least stable disease continued to receive single agent bevacizumab every 21 days until disease progression or unacceptable toxicity developed.

      Results
      The median age was 73 years old (range 66-82 years); 17 (81%) patients were men; ECOC PS was 0 in 4 (19%) patients, 1 in 9 (43%) patients and 2 in 8 (38%) patients. The objective response rate was 30.3%, while disease control rate was 63.7%, respectively, and the median progression-free survival time was 4. 2 months. Grade 3/4 neutropenia, grade 3/4 thrombocytopenia occurred in 2(10%) patients, while grade 3/4 peripheral neuropathy occurred in 3(14%) patients and grade 3/4 fatigue had occurred in 4(19%) patients. No treatment-related deaths had been reported in this study.

      Conclusion
      Bevacizumab when given with paclitaxel and carboplatin exhibits activity in previously treated elderly patients with advanced NSCLC and has acceptable toxicity.